Recent Updates
Recently added Catalysts
A Positive Sentiment

Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System

Friday, September 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agilent Technologies has launched the Agilent S540MD Slide Scanner System in the U.S. after receiving FDA clearance. This new whole slide imaging digital scanner aims to enhance diagnostic efficiency in pathology laboratories, responding to the growing demand for high-throughput solutions in clinical settings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of the Agilent S540MD Slide Scanner System.
  • FDA clearance obtained for the new system.
  • Addresses increasing demand for high-throughput solutions.

Full Press Release Details

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, following FDA clearance. This launch underscores Agilent’s ongoing commitment to digital pathology, broadening its portfolio to address the increasing demand for high-throughput solutions in clinical laboratories.Pathology laboratories continue to face increasing pressure to improve diagnostic efficiency

Frequently Asked Questions

What is the Agilent S540MD Slide Scanner System?

The Agilent S540MD Slide Scanner System is a whole slide imaging digital scanner.

When was the Agilent S540MD launched in the U.S.?

The Agilent S540MD was launched in the U.S. following FDA clearance.

What does the new scanner address?

It addresses the increasing demand for high-throughput solutions in clinical laboratories.

Who announced the launch of the S540MD?

Agilent Technologies Inc. announced the launch of the S540MD Slide Scanner System.

ShareAdd on Google
Tags: A Viatris Investor Conferences Healthcare Agilent S540MD Slide Scanner digital pathology FDA clearance
Last updated: Sep 4, 2026

Biotech snapshot

Cash runway
$1758M liquidity · $0M/mo burn
Low dilution risk